logo
Bank of America likes this industrial turnaround story

Bank of America likes this industrial turnaround story

CNBC16-07-2025
Rockwell Automation could still be an attractive turnaround story for investors, even after its latest run, according to Bank of America. BofA upgraded the industrial automation stock to buy from neutral in a Wednesday note, raising its price target 14%, to $410 per share from $360. BofA's forecast implies about 18% upside from Tuesday's $346.49 close. Rockwell helps businesses update their operations while improving productivity, through what are called both "smart manufacturing" and "process solutions." Analyst Andrew Obin said that Rockwell is "starting to see the impact of its operational turnaround strategy," adding that the company's Logix platform is a strong catalyst for growth. Some of the turnaround involves roughly $250 million worth of cost cutting in 2025, which the analyst said the company is hoping to surpass. "We view ROK as a beneficiary from reshoring of U.S. manufacturing," Obin wrote in a 13-page report. "ROK has a strong position in the U.S. and international automation markets." "We are gaining conviction in the company's ability to execute and see both secular and cyclical tailwinds, both of which will drive better earnings power versus prior cycles," he continued. The analyst raised his earnings estimate for the fiscal fourth quarter ending in September to $3.17 per share, above the Wall Street consensus of $2.86, he said. Obin also lifted his fiscal 2026 earnings estimate to $13, "well above $11.43 consensus and growing +29% y/y," he said, noting Rockwell's efforts to expand margins are in "early innings and accelerating." "We model faster margin expansion in FY26E vs. FY25E as a reflection of volume leverage," the analyst said. "The company has telegraphed pricing trending above expectations." Rockwell shares have soared 54% in the past three months.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lenz Therapeutics price target raised to $53 from $44 at BofA
Lenz Therapeutics price target raised to $53 from $44 at BofA

Business Insider

time13 hours ago

  • Business Insider

Lenz Therapeutics price target raised to $53 from $44 at BofA

BofA analyst Jason Gerberry raised the firm's price target on Lenz Therapeutics (LENZ) to $53 from $44 and keeps a Buy rating on the shares. The firm cites the company's Vizz FDA approval and Q2 report the target increase. It believes Lenz's peak sales opportunity for Vizz is being underappreciated at current share levels. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

BofA Sees Huge Upside in Roblox (RBLX) as GAG Hits 21.3 Million Concurrent Users
BofA Sees Huge Upside in Roblox (RBLX) as GAG Hits 21.3 Million Concurrent Users

Yahoo

time2 days ago

  • Yahoo

BofA Sees Huge Upside in Roblox (RBLX) as GAG Hits 21.3 Million Concurrent Users

Roblox Corporation (NYSE:RBLX) ranks among the . BofA Securities reaffirmed its Buy rating on Roblox Corporation (NYSE:RBLX) and increased its price target from $103 to $133 on July 28. The price target hike comes after the successful launch of Grow a Garden (GAG) on March 26. According to BofA, GAG's launch ranks as the largest video game launch ever, with 21.3 million concurrent users (CCUs), surpassing Fortnite's launch. According to analyst Omar Dessouky of BofA Securities, the RBLX stock has nearly doubled in value since the debut of GAG. The analyst states that GAG's performance shows that the Roblox platform can yield industry-leading KPIs for developers and generate several hits. Additionally, according to BofA Securities, the majority of investors they interviewed had been Roblox enthusiasts for at least two years, indicating that speculative newcomers were not the main force behind the most recent stock boom. Roblox Corporation (NYSE:RBLX) is a video game developer based in California. With 2.9 million developers, 6 million active experiences, and 88.9 million active users per day, Roblox Corporation (NYSE:RBLX) extends beyond the traditional definition of a video game by combining its digital currency and offering an extensive range of unique virtual experiences. While we acknowledge the potential of RBLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects

Yahoo

time2 days ago

  • Yahoo

BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is . On July 11, BofA Securities initiated coverage of the stock with a 'Buy' rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company's Taysha gene therapy TSHA-102 under development for Rett Syndrome. Copyright: dolgachov / 123RF Stock Photo The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones. Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity. Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotech company focused on developing and bringing to market gene therapies for serious monogenic disorders affecting the central nervous system. It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies. While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store